Micron Solutions (MICRD) 10-K 22 Mar 17 2016 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2016	Mar. 22, 2017	Jun. 30, 2016
Document and Entity Information [Abstract]
Entity Registrant Name	ARRHYTHMIA RESEARCH TECHNOLOGY INC /DE/
Entity Central Index Key	819,689
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Document Type	10-K
Document Period End Date	Dec. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	FY
Amendment Flag	false
Entity Common Stock, Shares Outstanding		2,820,999
Entity Public Float			$ 17,660,327
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 380,381	$ 272,291
Trade accounts receivable, net of allowance for doubtful accounts of $30,000 at December 31, 2016 and $60,000 at December 31, 2015	2,276,608	2,798,353
Inventories	3,060,085	2,118,712
Prepaid expenses and other current assets	614,362	593,716
Total current assets	6,331,436	5,783,072
Property, plant and equipment, net	6,440,911	6,626,069
Assets held for sale, net	688,750	665,000
Intangible assets, net	30,093	18,645
Other assets	156,231	243,319
Total assets	13,647,421	13,336,105
Current liabilities:
Revolving line of credit, current portion	1,785,795	0
Equipment line of credit, current portion	102,500	35,718
Term notes payable, current portion, net of debt issuance costs	487,468	589,635
Subordinated promissory notes, net of discount	0	473,135
Accounts payable	1,744,261	1,553,388
Accrued expenses and other current liabilities	333,361	275,777
Customer deposits	122,290	93,407
Deferred revenue, current	224,988	272,837
Total current liabilities	4,800,663	3,293,897
Long-term liabilities:
Revolving line of credit, non-current portion	0	1,511,495
Equipment line of credit, non-current portion	0	301,132
Term notes payable, non-current portion, net of debt issuance costs	1,970,863	1,074,723
Subordinated promissory notes, net of discount	432,011	0
Deferred revenue, non-current	156,953	272,181
Total long-term liabilities	2,559,827	3,159,531
Total liabilities	7,360,490	6,453,428
Commitments and Contingencies
Shareholders' equity:
Preferred stock, $0.001 par value; 2,000,000 shares authorized, none issued	0	0
Common stock, $0.01 par value; 10,000,000 shares authorized; 3,926,491 issued, 2,820,999 outstanding at December 31, 2016 and 3,926,491 issued, 2,801,639 outstanding at December 31, 2015	39,265	39,265
Additional paid-in-capital	11,457,320	11,381,536
Treasury stock at cost, 1,105,492 shares at December 31, 2016 and 1,124,852 shares at December 31, 2015	(3,028,564)	(3,069,496)
Accumulated deficit	(2,181,090)	(1,468,628)
Total shareholders’ equity	6,286,931	6,882,677
Total liabilities and shareholders’ equity	$ 13,647,421	$ 13,336,105

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Consolidated Balance Sheets [Abstract]
Allowance for doubtful accounts receivable, current	$ 30,000	$ 60,000
Preferred stock, par value per share	$ 0.001	$ 0.001
Preferred stock, shares authorized	2,000,000	2,000,000
Preferred stock, shares issued	0	0
Common stock, par value per share	$ 0.01	$ 0.01
Common stock, shares authorized	10,000,000	10,000,000
Common stock, shares issued	3,926,491	3,926,491
Common stock, shares outstanding	2,820,999	2,801,639
Treasury stock, shares	1,105,492	1,124,852

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Consolidated Statements of Operations and Comprehensive Loss [Abstract]
Net sales	$ 19,638,217	$ 21,495,184
Cost of sales	16,739,526	18,332,346
Gross profit	2,898,691	3,162,838
Selling and marketing	1,153,044	1,086,586
General and administrative	2,151,244	2,355,484
Research and development	97,234	241,100
Total operating expenses	3,401,522	3,683,170
Net loss from continuing operations	(502,831)	(520,332)
Other expense:
Interest expense	(259,762)	(260,300)
Other income (expense), net	50,131	(10,212)
Total other expense, net	(209,631)	(270,512)
Loss from continuing operations before income taxes	(712,462)	(790,844)
Income tax provision		932
Loss from continuing operations	(712,462)	(791,776)
Discontinued Operations:
Income from discontinued operations, net of tax provision of $0 for the years ended December 31, 2016 and 2015	0	362,610
Net loss	(712,462)	(429,166)
Other comprehensive loss:
Reclassification of gains from foreign currency translation		(42,502)
Comprehensive loss	$ (712,462)	$ (471,668)
Earnings (loss) per share - basic
Continuing operations	$ (0.25)	$ (0.28)
Discontinued operations	0	0.13
Earnings (loss) per share - basic	(0.25)	(0.15)
Earnings (loss) per share - diluted
Continuing operations	(0.25)	(0.28)
Discontinued operations	0	0.13
Earnings (loss) per share - dilutes	$ (0.25)	$ (0.15)
Weighted average common shares outstanding - basic	2,816,516	2,784,757
Weighted average common shares outstanding - diluted	2,816,516	2,784,757

Consolidated Statements of Ope5

Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Consolidated Statements of Operations and Comprehensive Loss [Abstract]
Tax provision, discontinued operations	$ 0	$ 0

Consolidated Statements of Chan

Consolidated Statements of Changes in Shareholders' Equity - USD ($)	Common Stock [Member]	Additional paid-in capital [Member]	Treasury stock [Member]	Accumulated other comprehensive income [Member]	Accumulated deficit [Member]	Total
Stockholders' Equity Attributable to Parent, Beginning Balance at Dec. 31, 2014	$ 39,265	$ 11,336,693	$ (3,133,883)	$ 42,502	$ (1,039,462)	$ 7,245,115
Shares, Outstanding, Beginning Balance at Dec. 31, 2014	3,926,491		1,148,152
Accumulated comprehensive income from unrealized gains and losses in currency translation		(51)		$ (42,502)		(42,553)
Share-based compensation - options		29,178				$ 29,178
Issuance of common stock from treasury, shares			(23,300)			(23,300)
Issuance of common stock from treasury		15,716	$ 64,387			$ 80,103
Net loss					(429,166)	(429,166)
Stockholders' Equity Attributable to Parent, Ending Balance at Dec. 31, 2015	$ 39,265	11,381,536	$ (3,069,496)		(1,468,628)	6,882,677
Shares, Outstanding, Ending Balance at Dec. 31, 2015	3,926,491		1,124,852
Share-based compensation - options		47,256				47,256
Change in the incremental fair value of warrants		18,310				$ 18,310
Issuance of common stock from treasury, shares			(15,000)			(15,000)
Issuance of common stock from treasury		10,218	$ 40,932			$ 51,150
Net loss					(712,462)	(712,462)
Stockholders' Equity Attributable to Parent, Ending Balance at Dec. 31, 2016	$ 39,265	$ 11,457,320	$ (3,028,564)		$ (2,181,090)	$ 6,286,931
Shares, Outstanding, Ending Balance at Dec. 31, 2016	3,926,491		1,109,852

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Cash flows from operating activities:
Net loss	$ (712,462)	$ (429,166)
Income from discontinued operations	0	(362,610)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Loss on sale of property, plant and equipment	0	13,320
Change in fair value of assets held for sale	(23,750)	0
Depreciation and amortization	1,541,006	1,464,588
Impairment of intangibles	0	118,318
Non-cash interest expense	27,186	27,683
Change in allowance for doubtful accounts	(30,000)	15,000
Share-based compensation expense	47,256	29,178
Changes in operating assets and liabilities:
Accounts receivable	551,745	723,394
Inventories	(941,373)	395,529
Prepaid expenses and other current assets	(25,228)	(94,547)
Other non-current assets	112,604	301,522
Accounts payable	190,873	(303,768)
Accrued expenses and other current liabilities	38,618	(90,426)
Other non-current liabilities	(115,228)	(338,249)
Net cash provided by (used in) operating activities	661,247	1,469,766
Cash flows from investing activities:
Purchases of property, plant and equipment	(1,354,091)	(1,182,541)
Proceeds from sale of property, plant and equipment	0	35,700
Cash paid for patents and trademarks	(13,205)	(6,176)
Net cash provided by (used in) investing activities	(1,367,296)	(1,153,017)
Cash flows from financing activities:
Proceeds from (payments on) revolving line of credit, net	274,300	(560,000)
Proceeds from equipment line of credit	647,351	752,635
Proceeds from term note payable	500,000	0
Payments on term notes payable	(587,799)	(526,594)
Payment of debt issuance costs	(20,863)	0
Payment on subordinated debt	(50,000)	0
Proceeds from stock option exercises	51,150	80,103
Net cash provided by (used in) financing activities	814,139	(253,856)
Net increase (decrease) in cash and cash equivalents	108,090	62,893
Cash and cash equivalents, beginning of period	272,291	209,398
Cash and cash equivalents, end of period	380,381	272,291
Supplemental Cash Flow Information
Cash paid for interest	233,330	222,237
Non-cash activities:
Reclassified assets held for sale	0	665,000
Change in incremental value of warrants	18,310
Non-cash payoff of revolver as part of refinancing	500,000
Non-cash payoff of notes as part of refinancing	457,828
Equipment line of credit converted to term notes payable	$ 1,524,115	$ 415,785

Description of Business

Description of Business	12 Months Ended
	Dec. 31, 2016
Description of Business [Abstract]
Description of Business	1. De scription of Business  Arrhythmia Research Technology ® , Inc., (“ART”), through its wholly-owned subsidiary, Micron Products ® , Inc. ("Micron", and collectively with ART, the "Company") is a diversified contract manufacturing organization (“CMO”) that produces highly-engineered, innovative components requiring precision machining and thermoplastic injection molding. The Company also manufactures components, devices and equipment for military, law enforcement, automotive and consumer products applications. The Company's capabilities include the production and sale of silver/silver chloride coated and conductive resin sensors used as consumable component parts in the manufacture of integrated disposable electrophysiological sensors . The Company’s machining operations produce quick-turn, high volume and patient-specific orthopedic implant components and instruments. The Company also has custom thermoplastic injection molding capabilities as well as a full array of design, engineering, production services and management. The Company competes globally, with nearly forty percent of its revenue derived from exports.  The Company ’s shares have traded on the NYSE MKT since 1992 under t he symbol HRT. The Company has grown organically and through acquisitions. Today, the Company has diversified manufacturing capabilities with the capacity to participate in full product life-cycle activities from early stage development and engineering and prototyping to full scale manufacturing as well as packaging and product fulfillment services. The Company's subsidiary, RMDDxUSA Corp. and its Prince Edward Island subsidiary RMDDx Corporation (collectively "WirelessDx"), discontinued operations in 2012, filed for relief under Chapter 7 (Liquidation) of the United States Bankruptcy Code in May 2014 and in March 2015, the Chapter 7 Order was formally discharged and the case was closed (see Note 12).  Operating matters and liquidity  The revolver under the Company's credit facility has a maturity date of June 2017 (see Note 5). At December 31, 2016 , the outstanding balance on the revolver was $1,785,795 . The Company believes that cash flows from its operations, together with its existing working capital, increased booked orders, the renewal of the revolver and other resources, will be sufficient to fund operations at current levels and repay debt obligations over the next twelve months and beyond; however, there can be no assurance that the Company will be able to do so.  Assessment of going concern  In 2016, the Company adopted new accounting standard ASU No. 2014-15, “Presentation of Financial Statements - Going Concern (Subtopic 205-40), Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern”. The new accounting standard requires management to evaluate whether there are conditions that give rise to substantial doubt as to the Company’s ability to continue as a going concern within one year from the date of issuance of these financial statements. Substantial doubt exists when conditions and events, considered in the aggregate, indicate that it is probable that a company will be unable to meet its obligations as they become due within one year after the financial statement issuance date. Management evaluations include identifying relevant conditions and events that were known and reasonably knowable as of the date these financial statements have been issued.  The Company identified certain conditions and events which in the aggregate required management to perform an assessment of the Company’s ability to continue as a going concern. These conditions include the Company’s ability to renew the revolver which matures in June 2017, negative financial history and the Company’s limited liquidity to meet the working capital needs to support the Company’s operations.  Management’s assessment included an analysis of the Company’s financial forecasts. Management’s assessment also considered the Company’s history of meeting financial covenants and being able to renew and refinance its debt obligations. Based on the anticipated renewal of the Company’s revolver, cash forecasts, expected fulfillment of booked orders from existing customers, new customer prospects, and the closing on the sale of certain real estate held for sale, the Company expects to continue to meet its financial covenants and its obligations for the next year.

Accounting Policies

Accounting Policies	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Accounting Policies	2. Accounting Policies  Principles of consolidation  The consolidated financial statements (the "financial statements") include the accounts of ART, Micron and WirelessDx. WirelessDx is presented herein as discontinued operations. All intercompany balances and transactions have been eliminated in consolidation.  Use of estimates  The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.  Revenue r ecognition  Revenue is recorded when all criteria for revenue recognition have been satisfied . R evenue is recognized in the period when persuasive evidence of an arrangement with a customer exists, the products are shipped and title has transferred or when exclusive control has been transferred to the customer , the price is fixed or determinable and collection is probable. The Company has entered into supply agreements with certain foreign customers where revenue is not recognized when the product is shipped but instead is recognized when the customer consumes the product.  The Company enters into arrangements containing multiple elements which may include a combination of the sale of molds, tooling, engineering and validation services ("tooling") and production units. The Company has determined that certain engineering and tooling arrangements, and the related production units, represent one unit of accounting , based on an assessment of the respective standalone value. When the Company determines that an arrangement represents one unit of accounting, the revenue is deferred over the estimated product life-cycle, based upon historical knowledge of the customer, which is generally one to three years. The Company carries the sales and tooling costs, associated with the related arrangement, as deferred revenue and other current and non-current assets, respectively, on the Company's balance sheet. As the deferred revenue is amortized to sales over the product lifecycle , the associated prepaid tooling costs are amortized to cost of sales.  The Company cannot effectively predict short-term or long-term production volume in a consistent and meaningful manner , due to the nature of these molds and associated products. Therefore, the Company is unable to account for the transactions under the Units of Production method and management has determined the most appropriate amortization method to be the Straight-Line method.  The Company may from time to time, at the customer's request, enter into a bill and hold arrangement. The Company evaluates the nature of the arrangement including, but not limited to (i) the customer's business purpose, (ii) the transfer of risk of ownership to the customer and (iii) the segregation of inventory, along with other elements in accordance with relevant accounting guidance to determine the appropriate method of revenue recognition for each arrangement.  Revenue for software license sales is recognized when licenses are sold as the revenue cycle is completed with no warranty, returns or technical support to customers. Total revenue from software sales was immaterial in relation to consolidated revenues.  Fair value of financial instruments  The carrying amount reported in the balance sheets for cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate their fair value due to the immediate or short-term nature of such instruments. The carrying value of debt approximates fair value since it provides for market terms and interest rates.  Concentration of credit risk  Financial instruments which potentially expose the Company to concentrations of credit risk consist primarily of accounts receivable and cash and cash equivalents. It is the Company’s policy to place its cash in high quality financial institutions. The Company does not believe significant credit risk exists above federally insured limits with respect to these institutions.  Accounts receivable are customer obligations due under normal trade terms. A large portion of the Company's products are sold to large diversified medical, military and law enforcement product manufacturers. The Company does not generally require collateral for its sales; however, the Company believes that its terms of sale provide adequate protection against credit risk. While the Company has a strong record of collecting on its receivables, the Company maintains Accounts Receivables insurance in order to mitigate concentration of credit risk where our top five customers in revenue constituted 46% of the Accounts Receivables at December 31, 2016 as compared to 51% at December 31, 2015.  During the year ended December 31, 2016 , the Company had net sales to two customers constituting 19% and 12% of total 2016 net sales. Accounts receivable from these two customers at December 31, 2016 was 26% and 7% , respectively , of the total accounts receivable balance at year end. During the year ended December 31, 2015 , the Company had net sales to two customers constituting 16% and 13% , respectively, of total 2015 net sales. Accounts receivable from the two customers at December 31, 2015 was 9% for each of the total accounts receivable balance at year end.  Cash and cash equivalents  Cash and cash equivalents consist of cash on hand and on deposit in high quality financial institutions with maturities of three months or less at the time of purchase.  Accounts r eceivable and a llowance for d oubtful a ccounts  Accounts receivable represent amounts invoiced by the Company. Management maintains an allowance for doubtful accounts based on information obtained regarding individual accounts and historical experience. Amounts deemed uncollectible are written off against the allowance for doubtful accounts. Bad debts have not had a significant impact on the Company’s financial position, results of operations and cash flows.  The Company insures receivables for certain customers based upon several factors. Such factors include the customer’s payment term s, ordering patterns and volume requirements, the customer’s payment history, or general economic conditions of the region in which a customer is located.  Inventories  The Company values its inventory at the lower of average cost, first-in-first-out (FIFO) or net realizable value. The Company reviews its inventory for quantities in excess of production requirements, obsolescence and for compliance with internal quality specifications. A review of inventory on hand is made at least annually and obsolete inventory may be disposed of and/or recycled. Any adjustments to inventory would be equal to the difference between the cost of inventory and the estimated net market value based upon assumptions about future demand, market conditions and expected cost to distribute those products to market. The Company also has supply agreements with certain foreign customers to hold inventory at the customer’s warehouses.  Property, plant and equipment  Property, plant and equipment are recorded at cost and include expenditures which substantially extend their useful lives. Depreciation on property, plant and equipment is calculated using the straight-line method over the estimated useful lives of the assets. Expenditures for maintenance and r epairs are charged to earnings as incurred. When equipment is retired or sold, the resulting gain or loss is reflected in earnings.  Assets held for sale  Property classified as held for sale is measured at the lower of its carrying value or fair value less cost to sell. Gains or losses are recognized for any subsequent changes to fair value less cost to sell; however, gains that may be recognized are limited by cumulative losses previously recognized. Property held for sale is not depreciated.  Property is classified as held for sale in the period in which management with the appropriate authority commits to a plan to sell the asset; the asset is available for immediate sale in its present condition subject only to terms that are usual and customary for sales of such assets; an active program to locate a buyer and other actions required to complete the plan of sale have been initiated; the sale of the property or asset within one year is probable and will qualify for accounting purposes as a sale; the asset is being actively marketed for sale at a price that is reasonable in relation to its current fair value; and actions required to complete the plan of sale indicate that it is unlikely that significant changes to the plan will be made or that the plan will be withdrawn. Long-lived assets classified as held for sale are presented separately in the statement of financial position of the current period (see Note 4) .  Fair value hierarchy  The Company groups its assets and liabilities generally measured at fair value in three levels, based on the markets in which the assets and liabilities are traded and the reliability of the assumptions used to determine fair value.  Level 1 – Valuation is based on quoted prices in active markets for identical assets or liabilities. Valuations are obtained from readily available pricing sources.  Level 2 – Valuation is based on observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.  Level 3 – Valuation is based on unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using unobservable inputs to pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation.  In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the investment. The Company recognizes transfers between levels at the end of the reporting period. There were no changes in levels in 2016.  At December 31, 2016 and 2015, assets held for sale is the only item in the financial statements reflected at fair value. Assets held for sale are considered level 3. The fair value of assets held for sale was determined using the sales price per the amended purchase and sale agreement, less the estimated cost to sell (see Note 4) .  Long-lived and intangible assets  The Company assesses the impairment of long-lived and intangible assets with finite lives annually or whenever events or changes in circumstances indicate that the carrying value may not be fully recoverable. Based upon the annual review, the Company recorded no impairment charges in 2016 and recorded $118,318 in impairment charges in 201 5 .  In 2015, the Company reviewed unamortized costs for patents pending. As a result of this review, the Company determined that the patents pending related to the Triggering Recharging and Wireless Transmission of Remote Patient Monitoring Device, as well as the Seed-Beat Selection Method for Signal-Averaged Electrocardiography were no longer patentable and recorded an impairment charge of $103,287 for the full costs of these patents pending. Additionally, after a review of trade names, the Company determined that the Leominster Tool & Die name no longer provided any future economic benefit and recorded an impairment charge of $15,031 for the remaining unamortized balance of the trade names.  Intangible assets consist of the following:      Estimated December 31, 2016 December 31, 2015  Useful Life Accumulated Accumulated  (in years) Gross Amortization Net Gross Amortization Net  Patents and trademarks 10 $ 26,290 $ 9,738 $ 16,552 $ 26,290 $ 7,981 $ 18,309  Patents and trademarks pending — 13,541 — 13,541 336 — 336  Total intangible assets $ 39,831 $ 9,738 $ 30,093 $ 26,626 $ 7,981 $ 18,645  Amortization expense related to intangible assets, excluding the above noted 2015 impairment charge s , was $1,757 and $3,235 in 2016 and 2015 , respectively. Estimated future annual amortization expense for currently amortizing intangible assets is expected to approximate $1,757 .  Income taxes  The Company recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between the financial statement and tax bases of assets and liabilities using tax rates in effect for the year in which the differences are expected to reverse.  The Company follows the provisions of FASB ASC 740, “Accounting for Uncertainty in Income Taxes—An Interpretation of FASB No. 109.” FASB ASC 740 provides detailed guidance for the financial statement recognition, measurement and disclosure of uncertain tax positions recognized in the financial statements in accordance with SFAS No. 109. Tax positions must meet a “more-likely-than-not” recognition threshold at the effective date to be recognized upon the adoption of FASB ASC 740 and in subsequent periods. No interest and penalties related to uncertain tax positions were accrued at December 31, 201 6 . The Company ’s primary operations are located in the US. Tax years ended December 31, 201 3 or later remain subject to examination by the IRS and state taxing authori ties.  Share-based compensation  Share-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized as an expense over the employee’s requisite service period (generally the vesting period of the share-based grant).  Comprehensive loss  In 201 6 and 201 5 , the Company has other comprehensive loss of $0 and $42,502 , respectively. In 2016 , the change in comprehensive loss was a result of the bankruptcy of RMDDx USA Corp . (see Note 12).  Earnings per share data  Basic earnings (loss) per share is computed by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding. The computation of diluted earnings (loss) per share is similar to the computation of basic earnings (loss) per share except that the denominator is increased to include the average number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued. In addition, the numerator is adjusted for any changes in net income (loss) that would result from the assumed conversions of those potential shares.  Research and development  Research and development expenses include costs directly attributable to conducting research and development programs primarily related to the development of a unique process to improve silver coating during the manufacturing processes, including the design and testing of specific process improvements for certain medical device components. Such costs include salaries, payroll taxes, employee benefit c osts, materials, supplies, depreciation on research equipment, and services provided by outside contractors. All costs associated with research and development programs are expensed as incurred.  Recently Issued Accounting Pronouncements  In the normal course of business, management evaluates all new accounting pronouncements issued by the Financial Accounting Standard Board (“FASB”), Securities and Exchange Commission (“SEC”), Emerging Issues Task Force (“EITF”), or other authoritative accounting bodies to determine the potential impact they may have on the Company’s Consolidated Financial Statements. Based upon this review, except as noted below, management does not expect any of the recently issued accounting pronouncements, which have not already been adopted, to have a material impact on the Company’s consolidated financial statements.  In August 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-15, “ Statement of Cash Flows (Topic 230) Classification of Certain Cash Receipts and Cash Payments” . This standard provides guidance for eight cash flow classification issues in current GAAP. The standard is effective for interim and annual reporting periods beginning after December 15, 2017. The Company is currently evaluating the impact that the standard will have on its consolidated financial statements.  In March 2016, the FASB issued ASU No. 2016-09, “Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting”. The standard is intended to simplify several areas of accounting for share-based compensation arrangements, including the income tax impact, classification on the statement of cash flows and forfeitures. The standard is intended to reduce the cost and complexity with maintaining or improving the usefulness of information provided to users of financial statements. The standard is effective for interim and annual reporting periods beginning after December 15, 2016 and early adoption is permitted. The Company is currently evaluating the impact that the standard will have on its consolidated financial statements.  In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842),” which requires companies to recognize all leases as assets and liabilities on the consolidated balance sheet. The standard retains a distinction between finance leases and operating leases, and the classification criteria for distinguishing between finance leases and operating leases are substantially similar to the classification criteria for distinguishing between capital leases and operating leases in the current accounting literature. The result of retaining a distinction between finance leases and operating leases is that under the lessee accounting model in Topic 842, the effect of leases in a consolidated statement of comprehensive income and a consolidated statement of cash flows is largely unchanged from previous GAAP. The amendments in this standard are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Earlier application is permitted. The Company is currently evaluating the impact that the adoption of this standard will have on its consolidated financial statements.  In November 2015, the FASB issued ASU No. 2015-17, "Balance Sheet Classification of Deferred Taxes" which requires the presentation of deferred tax assets and deferred tax liabilities, and any related valuation allowances, as noncurrent on the consolidated balance sheets. The standard is effective for interim and annual reporting periods beginning after December 15, 2016 and early adoption is permitted. The Company is currently evaluating the impact that the standard will have on its consolidated financial statements.  In July 2015, the FASB issued ASU No. 2015-11, “Simplifying the Measurement of Inventory,” which simplifies the subsequent measurement of inventory by requiring inventory to be measured at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. This standard is effective for public business entities for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. The Company is currently assessing the impact of adopting this standard on its consolidated financial statements.  In April 2015, the FASB issued ASU No. 2015-03, "Simplifying the Presentation of Debt Issuance Costs". ASU 2015-03 requires that debt issuance costs be presented as a direct deduction from the carrying amount of the related debt liability, consistent with the presentation of debt discounts. Prior to the issuance of ASU 2015-03, debt issuance costs were required to be presented as deferred charge assets, separate from the related debt liability. ASU 2015-03 does not change the recognition and measurement requirements for debt issuance costs. The Company adopted ASU 2015-03 as of December 31, 2016, and applied its provisions retrospectively. The adoption of ASU 2015-03 did not have an impact on the Company’s financial results nor did it represent a material change to the consolidated balances sheets.  In August 2014, the FASB issued ASU No. 2014-15, “Presentation of Financial Statements - Going Concern (Subtopic 205-40), Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern”, which requires management to assess a company’s ability to continue as a going concern and to provide related footnote disclosures in certain circumstances. The standard provides guidance on evaluating whether there are conditions or events that raise substantial doubt about an entity’s ability to continue as a going concern. Substantial doubt exists when conditions or events, considered in the aggregate, indicate that it is probable that the entity will be unable to meet its obligations as they become due within one year after the date that the financial statements are issued. The new standard is effective for the annual and interim periods ending after December 15, 2016. The Company adopted the standard in 2016 and management’s assessment has determined that certain disclosures required are included in these statements (see Note 1).  In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers” (“ASU 2014-09”). The core principle behind ASU No. 2014-09 is that an entity should recognize revenue in an amount that reflects the consideration to which the entity expects to be entitled in exchange for delivering goods and services. This model involves a five-step process that includes identifying the contract with the customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations in the contract and recognizing revenue when the entity satisfies the performance obligations. This ASU allows two methods of adoption; a full retrospective approach where historical financial information is presented in accordance with the new standard, and a modified retrospective approach where this ASU is applied to the most current period presented in the financial statements. In August 2015, the FASB issued ASU No 2015-14 “Revenue from Contracts with Customers: Deferral of the Effective Date,” which deferred the effective date of ASU 2014-09 to annual reporting periods beginning after December 15, 2017, with earlier application permitted as of annual reporting periods beginning after December 15, 2016. The Company is currently assessing the financial impact of adopting ASU 2014-09 and the methods of adoption; however, given the scope of the new standard, the Company is currently unable to provide a reasonable estimate regarding the financial impact or which method of adoption will be elected.  Reclassification of prior period balances  Amounts in prior year financial statements are reclassified when necessary to conform to the current year presentation , most notably debt issuance costs in according with ASU 2015-03 as described more fully above .

Inventories

Inventories	12 Months Ended
	Dec. 31, 2016
Inventories [Abstract]
Inventories	3. Inventories  Inventories consist of the following:      December 31, December 31,  2016 2015  Raw materials $ 1,027,474 $ 775,427  Work-in-process 537,858 265,113  Finished goods 1,494,753 1,078,172  Total $ 3,060,085 $ 2,118,712  The total cost of silver in our inventory as raw materials, as work-in-process or as a plated surface on finished goods had an estimated cost of $521,746 and $313,738 at December 31, 2016 and 2015 , respectively. The increase in inventory was due in part to increased finished goods inventory for sensors as a result of certain supply agreements with foreign customers.

Property, Plant and Equipment,

Property, Plant and Equipment, net	12 Months Ended
	Dec. 31, 2016
Property, Plant and Equipment, net [Abstract]
Property, Plant and Equipment, net	4. Property, Plant and Equipment, Net  Property, plant and equipment , net consist of the following:      Asset Lives December 31, December 31,  (in years) 2016 2015  Machinery and equipment 3 to 15 $ 16,647,302 $ 15,168,377  Building and improvements 5 to 25 3,986,715 3,978,387  Vehicles 3 to 5 90,713 90,713  Furniture, fixtures, computers and software 3 to 5 1,504,776 1,437,692  Construction in progress 402,099 682,069  Total property, plant and equipment 22,631,605 21,357,238  Less: accumulated depreciation (16,190,694) (14,731,169)  Property, plant and equipment, net $ 6,440,911 $ 6,626,069  For the year ended December 31, 2016 , the Company recorded $1,539,249 of depreciation expense compared to $1,461,353 for the year ended December 31, 2015 . There are no commitments related to the completion of construction in process as of December 31, 2016 .  In December 2015, the Company entered into a Letter of Intent with a Buyer (collectively the “Parties”) to sell two unoccupied buildings, with a total of approximately 52,000 square feet, and land, at its Fitchburg, Massachusetts campus. Subsequently, i n January 2016, the Parties entered into a Purchase and Sale Agreement (“Agreement”) for th is real estate to close within twelve months from the date of the Agreement . As these buildings were under agreement to be sold at December 31, 2015 they were classified as Assets Held for Sale valued at $665,000 as of December 31, 2015. The carrying value approximated the fa ir value less the cost to sell.  In December 2016, the Parties entered into a First Amendment to the Purchase and Sale Agreement (the “First Amendment”). The First Amendment extended the time to close to January 13, 2018. As consideration for extending the Agreement, the Buyer agreed to (i) release the $25,000 being held as a deposit to the Company; (ii) increase the purchase price by $25,000 ; (iii) pay the Company $4,000 per month as an extension fee beginning in January 2017 through January 2018, or the culmination of the Agreement, and (iv) pay the Company $7,500 per month for a 150 day additional extension, to June 2018, only for the purpose of the Buyer securing historical tax credits until the termination or culmination of the Agreement. The $25,000 deposit released to the Company is recorded as Other Income for the year ended December 31, 2016.  In January 2017, the Parties entered into a Second Amendment to the Purchase and Sale Agreement (the “Second Amendment”). The Second Amendment (i) permits the Buyer to assign the Agreement to a third party; (ii) extends the term of the $4,000 per month extension fee from January 2018 to March 2018 and (iii) and amends the term of the additional extension fee of $7,500 per month to April 2018 through July 2018.  As a result of the increase in sale price and other considerations, the Company determined t he carrying value at December 31, 2016 to be $688,750 . The increase in the carrying value is recorded as Other Income for the year ended December 31, 2016 and did not exceed the amount of previously recorded losses in accordance with appropriate accounting guidance.

Debt

Debt	12 Months Ended
	Dec. 31, 2016
Debt [Abstract]
Debt	5. Debt  The following tables set forth the items which comprise debt for the Company:      December 31, December 31,  2016 2015  Revolving line of credit $ 1,785,795 $ 1,511,495  Equipment line of credit $ 102,500 $ 336,850  Subordinated promissory notes, net of discount $ 432,011 $ 473,135   Term notes payable:  Commercial term loan, net of debt issuance costs $ 2,398,870 $ 668,246  Equipment term loans — 879,898  Equipment notes 59,461 116,214  Total term notes payable $ 2,458,331 $ 1,664,358   Total Debt $ 4,778,637 $ 3,985,838  Bank Debt  The Company has a multi-year credit facility with a Massachusetts based bank . At December 31, 2016 this credit facility consisted of a revolving line of credit (the "revolver"), a commercial term loan and an equipment line of credit . The debt is secured by substantially all assets of the Company with the exception of real property.  At December 31, 2015 the credit facility included a revolver, a commercial term loan, two equipment term loans and an equipment line of credit. In June of 2016 the equipment line of credit converted to a term loan . In November 2016 these four borrowings , along with $500,000 from the revolver, were consolidated into a single commercial term loan as further described below.  Revolver  The revolver provides for borrowings up to 80% of eligible accounts receivable and 50% of eligible raw materials inventory. The interest rate on the revolver is calculated at the bank's prime rate plus 0.25% ( 4.0% at December 31, 2016 ). The revolver has a maturity date of June 2017. Amounts available to borrow under the revolver are $727,156 at December 31, 2016 . In November 2016 the Company refinanced and consolidated $500,000 from the revolver into a new term loan as further described below.  Commercial term loan  In November 2016 , th e Company refinanced its bank term debt, including the commercial term loan and three equipment term loans, along with $500,000 from the revolver, into a new $2,481,943 consolidated five year commercial term loan with a maturity date in November 2021. The interest rate on the loan is a fixed 4.65% per annum and the loan requires monthly payments of principal and interest of approximately $46,500 .  Equipment line of credit and equipment term loans  In March 2013, the Company entered into an equipment line of credit that allowed for advances of up to $1.0 million and included a one -year draw period during which payments were interest only. The draw period ended in March 2 014 and the then outstanding balance on the equipment line of credit of $740,999 was converted to an equipment term loan with a five -year term, maturing in March 2019 . In November 2016, the outstanding principal and accrued interest of $380,791 on the equipment term loan was refinanced and consolidated into a new term loan as described above.  In June 2014, the Company entered into an equipment line of credit that allowed for advances of up to $1.0 million and included a one -year draw period during which payments were interest only. The draw period ended in June 2015 and the then outstanding balance on the equipment line of credit of $415,785 was converted to an equipment term loan with a five -year term, maturing in June 2020 . In November 2016, the outstanding principal and accrued interest of $315,272 on the equipment term loan was refinanced and consolidated into a new term loan as described above.  In June 2015, the Company entered into a n equipment line of credit that allowed for advances of up to $1.0 million and included a one -year draw period during which payments were interest only. At December 31, 2015, the Company ha d drawn $336,850 on the equipment line of credit. The draw period ended in June 2016 and the then outstanding balance on the equipment line of credit of $881,701 was converted to an equipment term loan with a five -year term, maturing in June 2021. In November 2016, the outstanding principal and accrued interest of $832,420 on the equipment term loan was refinanced and consolidated into a new term loan as described above. In November 2016, the Company entered into a new equipment line of credit that allows for advances of up to $1.0 million under the Company's multi-year credit facility. At December 31, 201 6 , $102,500 has been drawn on the new equipment line of credit. The term of this equipment line of credit is six years, maturing in November 2022, inclusive of a maximum one -year draw period. Repayment shall consist of monthly interest only payments, equal to the bank's prime rate plus 0.25% as to each advance commencing on the date of the loan through the earlier of: (i) one year from the date of the loan or (ii) the date upon which the equipment line of credit is fully advanced (the “Conversion Date”). On the Conversion Date, principal and interest payments will be due and payable monthly in an amount sufficient to pay the loan in full based upon an amortization schedule commensurate with the remaining term of the loan.  Debt issuance costs  The amount of the commercial term loan presented in the table above is net of debt issuance costs of $45,858 and $45,929 at December 31, 2016 and 2015 respectively.  Bank covenants  The bank facility contains both financial and non-financial covenants. The financial covenants include maintaining certain debt coverage and leverage ratios. The non-financial covenants relate to various matters including notice prior to executing further borrowings and security interests, mergers or consolidations, acquisitions, guarantees, sales of assets other than in the normal course of business, leasing, changes in ownership and payment of dividends. The Company was in compliance with all bank covenants as of December 31, 2016 .  Other debt  Equipment notes  In January 2013, the Company entered into two equipment notes totaling $272,500 with a financing company to acquire production equipment. The notes bear interest at 4.66% and require monthly payments of principal and interest totaling approximately $5,000 over the term of five years.  Subordinated promissory notes  In December 2013, the Company completed a private offering in which the Company sold an aggregate of $500,000 in subordinated promissory notes. The unsecured notes required quarterly interest-only payments at a rate of 10% per annum for the first two years . I n December 2015, the interest rate increased to 12% per annum . The Company’s two largest beneficial owners of stock and a director participated in the private offering as follows: REF Securities, LLP, beneficial owner of approximately 13% of the Company’s common stock, invested $100,000 in the offering; the Chambers Medical Foundation (the “Foundation”), beneficial owner of approximately 10% of the Company’s common stock, invested $100,000 in the offering; and Mr. E.P. Marinos, a director, invested $50,000 in the offering. The Company’s Chairman of the Board is a co-trustee of the Foundation but has held no dispositive powers since his appointment as such. In October 2016 , the Company and six of the seven investors in the private offering, aggregating $450,000 of the notes, including the three related parties holding $250,000 of the notes, agreed to extend the maturity dates of the notes to December 31, 2018 at a rate of 10% per annum. One investor did not extend the maturity date and that $50,000 note was paid at maturity in December 2016. The notes are subordinated to all indebtedness of the Company pursuant to its multi-year bank credit facility.  In connection with the subordinated promissory notes, the Company issued 100,000 warrants to purchase the Company's common stock , including 20,000 warrants to REF Securities, LLP, 20,000 warrants to the Foundation and 10,000 warrants to Mr. Marinos. The warrants were exercisable through December 2016 at an exercise price of $3.51 per share. In 2014, 30,000 warrants were exercised , including 20,000 by the Foundation . No warrants were exercised in 2015 or 2016. In October 2016, in connection with the extension of the maturity dates of the subordinated promissory notes, the expiration date of the remaining 70,000 warrants was extended to December 31, 2018. The exercise price remained unchanged at $3.51 per share. The 70,000 warrants remain unexercised at December 31, 2016.  The Company calculated the incremental fair value of extending the expiration date of the Notes and Warrants and determined that the amendment represented a debt modification in accordance with the guidance outlined in ASC-470, “Debt”. Using the Black-Scholes model, and the 10% test, the Company determined that the incremental fair value of the warrants to be $18,310 which was recorded as a reduction against the Notes and an increase in Additional Paid-in Capital.  Future maturities of debt for the years ending December 31 are as follows:      2017 2018 2019 2020 2021 Thereafter Total  Revolver $ 1,785,795 $ — $ — $ — $ — — $ 1,785,795  Subordinated promissory notes — 450,000 — — — — 450,000  Term debt and equipment notes 513,602 493,337 516,975 541,616 520,782 20,376 2,606,688  Total $ 2,299,397 $ 943,337 $ 516,975 $ 541,616 $ 520,782 20,376 $ 4,842,483

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2016
Income Taxes [Abstract]
Income Taxes	6. Income Taxes  The income tax provision consists of the following:      Years Ended  December 31,  2016 2015  Current:  Federal $ — $ —  State — 932  Total current income taxes — 932  Deferred:  Federal — —  State — —  Total deferred income taxes — —  Total income tax provision $ — $ 932  The components of deferred income taxes are as follows:      Years Ended  December 31,  2016 2015  Deferred tax assets:   Net operating loss carryforwards $ 3,671,600 $ 3,221,000  Federal and state tax credit carryforwards 493,800 608,000  Accruals and reserves 104,600 117,300  Stock based compensation 96,000 89,800  Patents and intangibles 51,100 68,100  Other long-term 500 45,500  Total long-term deferred tax assets 4,417,600 4,149,700   Deferred tax valuation allowance (3,812,900) (3,472,300)  Deferred tax assets, net of allowance 604,700 677,400   Property, plant and equipment (544,000) (612,800)  Prepaid expenses (60,700) (64,600)  Total deferred tax liabilities (604,700) (677,400)   Net deferred tax assets (liabilities) $ — $ —  In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax-planning strategies in making this asse ssment. As of December 31, 2016, the C ompany continues to maintain a valuation allowance against all of its deferred tax assets.  In 2016, the Company adopted ASU No. 2015-17, "Balance Sheet Classification of Deferred Taxes" . Under this new guidance the Company is required to present deferred tax assets and deferred tax liabilities, and any related valuation allowances, as noncurrent on the consolidated balance sheet s . There was no cumulative effect of the change and no impact to shareholders’ equity, results of operations or cash flows.  For the year ended December 31, 2016 , the Compan y has federal and state net operating loss carryforwards totaling $9,124,000 and $10,780,000 respecti vely, which begin to expire in 203 1 . The Company also had federal and state tax credit carryovers of $305,800 and $188,000 , respectively. The federal and state credits begin to expire in 202 7 and 201 6 , respectively.  The Company files a consolidated federal income tax return. The actual income tax provision differs from applying the Federal statutory income tax rate ( 34% ) to the pre-income tax loss from continuing operations as follows:      Years Ended  December 31,  2016 2015  Tax benefit computed at statutory rate $ (250,071) $ (145,442)  Increases (reductions) due to:  Change in valuation allowance 340,600 230,300  State income taxes, net of federal benefit (27,646) 615  Permanent differences 15,124 479  Tax credits (federal and state) (32,577) (108,194)  Differences on prior returns (federal and state) (45,430) 23,174  Income tax (benefit) provision $ — $ 932

Employee Benefit Plans

Employee Benefit Plans	12 Months Ended
	Dec. 31, 2016
Employee Benefit Plans [Abstract]
Employee Benefit Plans	7. Employee Benefit Plans  The Company sponsors an Employee Savings and Investment Plan under Section 401(k) of the Internal Revenue Code covering all eligible employees of the Company. Employees can contribute up to 90% of their eligible compensation to the maximum allowable by the IRS. The Company’s matching contributions are at the discretion of the Company. The Company’s matching contributions in 2016 and 2015 we re $41,072 and $47,858 , respectiv ely.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2016
Commitments and Contingencies [Abstract]
Commitments and Contingencies	8. Commitments and Contingencies  Legal matters  In the ordinary course of its business, the Company is involved in various legal proceedings involving a variety of matters. The Company does not believe there are any pending legal proceedings that will have a material impact on the Company’s financial position or results of operations.  Operating lease agreements  In 2016 , the Company entered into two operating leases for office equipment. The Company’s leases require future minimum annual lease payments o f $24,036 for fiscal years 2017 and 2018 , respec tively.

Shareholders' Equity

Shareholders' Equity	12 Months Ended
	Dec. 31, 2016
Shareholders' Equity [Abstract]
Shareholders' Equity	9. Shareholders’ equity  Common stock  In 201 6 , 15,000 shares were issued out of treasury as a result of the exercise of stock options and no warrants were exercised. In 201 5 , 23,300 shares were issued out of treasury as a result of the exercise of stock options and no warrants were exercised .  No dividends were declared or paid in 201 6 or 201 5 .  Warrants  In connection with the subordinated promissory notes issued in December 2013 (see Note 5) , the Company issued warrants to purchase 100,000 shares of the Company's common stock. The warrants were exercisable through December 2016 at an exercise price of $3.51 per share. In 2014, 30,000 warrants were exercised. No warrants were exercised in 2015 or 2016. In October 2016, in connection with the extension of the maturity dates of the subordinated promissory notes, the expiration date of the remaining 70,000 warrants was extended to December 31, 2018. The Company determined that the amendment represented a debt modification and did not constitute an extinguishment for accounting purposes (see Note 5). The exercise price remained unchanged at $3.51 per share. The 70,000 warrants remain unexercised at December 31, 2016.  Stock options and Share-Based Incentive Plan  In March 2010, the Company's Board of Directors adopted the Arrhythmia Research Technology, Inc. 2010 Equity Incentive Plan (the “Plan”). The Plan authorizes the issuance of an aggregate of 500,000 shares. The Plan provides the Company flexibility to award a mix of stock options, equity incentive grants, performance awards and other types of stock-based compensation to certain eligible employees, non-employee directors, or consultants and under which an aggregate of 500,000 shares have been reserved for such grants . The options granted have ten year contractual terms that vest annually between three to five -year terms.  At December 31, 2016, there were options to acquire an aggregate of 214,500 shares outstanding. At December 31, 2016, there were 273,000 shares available for future grants under the Plan , after giving effect to shares which became available for reissuance due to expired or forfeited options .  The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option pricing model that uses the assumptions noted in the following table. Expected volatilities are based on historical volatility of the Common Stock using historical periods consistent with the expected term of the options. The expected term of options granted under the Company’s equity incentive plan, all of which qualify as “plain vanilla,” is based on the average of the contractual term and the vesting period as permitted under SEC Staff Accounting Bulletin Nos. 107 and 110. The risk-free rate is based on the yield of a U.S. Treasury security with a term consistent with the option.  During 2016 and 2015 there were 45,000 and 62,500 new option grants, respectively. The assumptions used to measure the fair value of option grants in 2016 and 2015 were as follows:      Years Ended  December 31,  2016 2015  Expected option term 6.0 to 6.5 4.0 to 6.5  Expected volatility factor 23.7% to 24.4% 23.8% to 26.7%  Risk-free rate .90% to .99% .90% to 1.28%  Expected annual dividend yield —% —%  The following table sets forth the stock option transactions for the year ended December 31, 201 6 :      Weighted  Weighted average  Average remaining Aggregate  Number of Exercise contractual Intrinsic  options Price term (in years) Value  Outstanding at December 31, 2015 184,500 $ 6.21 6.80 $ 235,293  Granted 45,000 4.07  Exercised (15,000) 3.41  Outstanding at December 31, 2016 214,500 $ 5.96 7.12 $ 17,340  Exercisable at December 31, 2016 109,495 $ 6.90 5.47 $ 8,880  Exercisable at December 31, 2015 83,500 $ 6.60 4.73 $ 106,565  The total intrinsic value of options exercised during 2016 and 2015 were $30,600 and $60,197 , respectively. For the years ended December 31, 2016 and 2015 , share-based compensation expense related to stock options and the non-cash issuance of common stock amounted to $47,256 and $29,178 , respectively, and is included in general and administrative expenses. As of December 31, 2016 and 2015 , there was $134,354 and $134,160 of unrecognized compensation costs, respectively, related to non-vested share-based compensation arrangements granted under the stock option plan. This cost is expected to be recognized over a weighted average period of 2.7 years. The weighted average grant date fair value of options issued in 2016 was $1.05 .

Earnings Per Share

Earnings Per Share	12 Months Ended
	Dec. 31, 2016
Earnings Per Share [Abstract]
Earnings Per Share	10. Earnings per share  Basic earnings (loss) per share is computed by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding. The computation of diluted earnings (loss) per share is similar to the computation of basic earnings (loss) per share except that the denominator is increased to include the average number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued. In addition, the numerator is adjusted for any changes in net income (loss) that would result from the assumed conversions of those potential shares.  As of December 31, 2016, there were options to purchase 214,500 shares and warrants to purchase 70,000 shares of the Company's common stock outstanding, all of which were anti-dilutive. Therefore, none of these options or warrants were included in the calculation of loss per share in 2016 .  As of December 31, 2015, there were options to purchase 184,500 shares and warrants to purchase 70,000 shares of the Company's common stock outstanding , all of which were anti-dilutive . Therefore, none of these options or warrants were included in the calculation of loss per share in 2015 .  The following table shows the calculation of earnings (loss) per share for the years ended December 31, 2016 and 2015 :      Years Ended  December 31,  2016 2015  Loss from continuing operations $ (712,462) $ (791,776)  Income from discontinued operations, net of tax — 362,610  Net loss available to common shareholders $ (712,462) $ (429,166)  Basic EPS:  Weighted average common shares outstanding 2,816,516 2,784,757  Earnings (loss) per share - basic  Continuing operations $ (0.25) $ (0.28)  Discontinued operations — 0.13  Consolidated basic EPS $ (0.25) $ (0.15)  Diluted EPS:  Weighted average common shares outstanding 2,816,516 2,784,757  Assumed conversion of net common shares issuable under stock option plans — —  Assumed conversion of net common shares issuable under warrants — —  Weighted average common and common equivalent shares outstanding, diluted 2,816,516 2,784,757  Earnings (loss) per share - diluted  Continuing operations $ (0.25) $ (0.28)  Discontinued operations — 0.13  Consolidated diluted EPS $ (0.25) $ (0.15)

Industry and Geographic Segment

Industry and Geographic Segments	12 Months Ended
	Dec. 31, 2016
Industry and Geographic Segments [Abstract]
Industry and Geographic Segments	 11. Industry and Geographic Segments  The Company’s Chief Operating and Decision Maker ("CODM") manages the operations and reviews the results of operations as a single reporting unit. While the Company operates its business as one segment, the Company has diversified manufacturing capabilities as evidenced by its product offerings across several industry categories support ing customers around the globe.  The following table sets forth, for the periods indicated, the consolidated revenue and percentages of revenue from continuing operations derived from the sales of the Company's products and services in certain industries.      Revenue for the Years Ended December 31,  2016 % 2015 %  Medical $ 14,543,315 74 $ 16,770,788 78  Automotive/Industrial 3,787,312 19 2,839,926 13  Consumer Products 744,738 4 647,190 4  Military and Law Enforcement 383,254 2 943,603 4  Other 179,598 1 293,677 1  Total $ 19,638,217 100 $ 21,495,184 100  The following table sets forth, for the periods indicated, the consolidated revenue and percentages of revenue from continuing operations derived from the sales of all of the Company's products and services by geographic market.      Revenue for the Years Ended December 31,  2016 % 2015 %  United States $ 12,206,761 62 $ 13,199,188 61  Asia 4,283,180 22 4,774,910 22  Europe 1,677,100 9 1,662,318 9  Canada 1,268,817 6 1,607,445 7  Other 202,359 1 251,323 1  Total $ 19,638,217 100 $ 21,495,184 100

Discontinued Operations

Discontinued Operations	12 Months Ended
	Dec. 31, 2016
Discontinued Operations [Abstract]
Discontinued Operations	12. Discontinued Operations  The Company's subsidiary, RMDDxUSA Corp. and its Prince Edward Island subsidiary RMDDx Corporation (collectively "WirelessDx"), discontinued operations in 2012, filed for relief under Chapter 7 (Liquidation) of the United States Bankruptcy Code in 2014 and in March 2015, the Chapter 7 Order was formally discharged and the case was closed. In 2015, net income of $362,610 was recorded from discontinued operations as a result of the related write-off of the remaining liabilities and cumulative translation adjustment.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2016
Subsequent Events [Abstract]
Subsequent Events	13. Subsequent Events  Assets held for sale  In January 2017, the Company entered into a Second Amendment to the Purchase and Sale Agreement (the “Second Amendment”) related to the sale of certain real estate recorded as assets held for sale (see Note 4). The Second Amendment (i) permits the Buyer to assign the Agreement to a third party; (ii) extends the term of the $4,000 per month extension fee from January 2018 to March 2018 and (iii) and amends the term of the additional extension fee of $7,500 per month to April 2018 through July 2018.  Company name change  On March 9, 2017, Arrhythmia Research Technology, Inc. ( the “ Company ”) filed a Certificate of Amendment to its Certificate of Incorporation, as amended, with the Delaware Secretary of State to amend Article First of the Company’s Certificate of Incorporation to change the name of the corporation to “Micron Solutions, Inc.”. The effective date of the amendment is March 24, 2017.

Accounting Policies (Policies)

Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Principles of consolidation	Principles of consolidation  The consolidated financial statements (the "financial statements") include the accounts of ART, Micron and WirelessDx. WirelessDx is presented herein as discontinued operations. All intercompany balances and transactions have been eliminated in consolidation.
Use of estimates	Use of estimates  The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.
Revenue Recognition	Revenue r ecognition  Revenue is recorded when all criteria for revenue recognition have been satisfied . R evenue is recognized in the period when persuasive evidence of an arrangement with a customer exists, the products are shipped and title has transferred or when exclusive control has been transferred to the customer , the price is fixed or determinable and collection is probable. The Company has entered into supply agreements with certain foreign customers where revenue is not recognized when the product is shipped but instead is recognized when the customer consumes the product.  The Company enters into arrangements containing multiple elements which may include a combination of the sale of molds, tooling, engineering and validation services ("tooling") and production units. The Company has determined that certain engineering and tooling arrangements, and the related production units, represent one unit of accounting , based on an assessment of the respective standalone value. When the Company determines that an arrangement represents one unit of accounting, the revenue is deferred over the estimated product life-cycle, based upon historical knowledge of the customer, which is generally one to three years. The Company carries the sales and tooling costs, associated with the related arrangement, as deferred revenue and other current and non-current assets, respectively, on the Company's balance sheet. As the deferred revenue is amortized to sales over the product lifecycle , the associated prepaid tooling costs are amortized to cost of sales.  The Company cannot effectively predict short-term or long-term production volume in a consistent and meaningful manner , due to the nature of these molds and associated products. Therefore, the Company is unable to account for the transactions under the Units of Production method and management has determined the most appropriate amortization method to be the Straight-Line method.  The Company may from time to time, at the customer's request, enter into a bill and hold arrangement. The Company evaluates the nature of the arrangement including, but not limited to (i) the customer's business purpose, (ii) the transfer of risk of ownership to the customer and (iii) the segregation of inventory, along with other elements in accordance with relevant accounting guidance to determine the appropriate method of revenue recognition for each arrangement.  Revenue for software license sales is recognized when licenses are sold as the revenue cycle is completed with no warranty, returns or technical support to customers. Total revenue from software sales was immaterial in relation to consolidated revenues.
Fair value of financial instruments	Fair value of financial instruments  The carrying amount reported in the balance sheets for cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate their fair value due to the immediate or short-term nature of such instruments. The carrying value of debt approximates fair value since it provides for market terms and interest rates.
Concentration of credit risk	Concentration of credit risk  Financial instruments which potentially expose the Company to concentrations of credit risk consist primarily of accounts receivable and cash and cash equivalents. It is the Company’s policy to place its cash in high quality financial institutions. The Company does not believe significant credit risk exists above federally insured limits with respect to these institutions.  Accounts receivable are customer obligations due under normal trade terms. A large portion of the Company's products are sold to large diversified medical, military and law enforcement product manufacturers. The Company does not generally require collateral for its sales; however, the Company believes that its terms of sale provide adequate protection against credit risk. While the Company has a strong record of collecting on its receivables, the Company maintains Accounts Receivables insurance in order to mitigate concentration of credit risk where our top five customers in revenue constituted 46% of the Accounts Receivables at December 31, 2016 as compared to 51% at December 31, 2015.  During the year ended December 31, 2016 , the Company had net sales to two customers constituting 19% and 12% of total 2016 net sales. Accounts receivable from these two customers at December 31, 2016 was 26% and 7% , respectively , of the total accounts receivable balance at year end. During the year ended December 31, 2015 , the Company had net sales to two customers constituting 16% and 13% , respectively, of total 2015 net sales. Accounts receivable from the two customers at December 31, 2015 was 9% for each of the total accounts receivable balance at year end.
Cash and cash equivalents	Cash and cash equivalents  Cash and cash equivalents consist of cash on hand and on deposit in high quality financial institutions with maturities of three months or less at the time of purchase.
Accounts receivable and Allowance for Doubtful Accounts	Accounts r eceivable and a llowance for d oubtful a ccounts  Accounts receivable represent amounts invoiced by the Company. Management maintains an allowance for doubtful accounts based on information obtained regarding individual accounts and historical experience. Amounts deemed uncollectible are written off against the allowance for doubtful accounts. Bad debts have not had a significant impact on the Company’s financial position, results of operations and cash flows.  The Company insures receivables for certain customers based upon several factors. Such factors include the customer’s payment term s, ordering patterns and volume requirements, the customer’s payment history, or general economic conditions of the region in which a customer is located.
Inventories	Inventories  The Company values its inventory at the lower of average cost, first-in-first-out (FIFO) or net realizable value. The Company reviews its inventory for quantities in excess of production requirements, obsolescence and for compliance with internal quality specifications. A review of inventory on hand is made at least annually and obsolete inventory may be disposed of and/or recycled. Any adjustments to inventory would be equal to the difference between the cost of inventory and the estimated net market value based upon assumptions about future demand, market conditions and expected cost to distribute those products to market. The Company also has supply agreements with certain foreign customers to hold inventory at the customer’s warehouses. 
Property, plant and equipment	Property, plant and equipment  Property, plant and equipment are recorded at cost and include expenditures which substantially extend their useful lives. Depreciation on property, plant and equipment is calculated using the straight-line method over the estimated useful lives of the assets. Expenditures for maintenance and r epairs are charged to earnings as incurred. When equipment is retired or sold, the resulting gain or loss is reflected in earnings.
Assets held for sale	Assets held for sale  Property classified as held for sale is measured at the lower of its carrying value or fair value less cost to sell. Gains or losses are recognized for any subsequent changes to fair value less cost to sell; however, gains that may be recognized are limited by cumulative losses previously recognized. Property held for sale is not depreciated.  Property is classified as held for sale in the period in which management with the appropriate authority commits to a plan to sell the asset; the asset is available for immediate sale in its present condition subject only to terms that are usual and customary for sales of such assets; an active program to locate a buyer and other actions required to complete the plan of sale have been initiated; the sale of the property or asset within one year is probable and will qualify for accounting purposes as a sale; the asset is being actively marketed for sale at a price that is reasonable in relation to its current fair value; and actions required to complete the plan of sale indicate that it is unlikely that significant changes to the plan will be made or that the plan will be withdrawn. Long-lived assets classified as held for sale are presented separately in the statement of financial position of the current period (see Note 4) .
Fair value heirarchy	Fair value hierarchy  The Company groups its assets and liabilities generally measured at fair value in three levels, based on the markets in which the assets and liabilities are traded and the reliability of the assumptions used to determine fair value.  Level 1 – Valuation is based on quoted prices in active markets for identical assets or liabilities. Valuations are obtained from readily available pricing sources.  Level 2 – Valuation is based on observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.  Level 3 – Valuation is based on unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using unobservable inputs to pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation.  In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the investment. The Company recognizes transfers between levels at the end of the reporting period. There were no changes in levels in 2016.  At December 31, 2016 and 2015, assets held for sale is the only item in the financial statements reflected at fair value. Assets held for sale are considered level 3. The fair value of assets held for sale was determined using the sales price per the amended purchase and sale agreement, less the estimated cost to sell (see Note 4) .
Long-lived and intangible assets	Long-lived and intangible assets  The Company assesses the impairment of long-lived and intangible assets with finite lives annually or whenever events or changes in circumstances indicate that the carrying value may not be fully recoverable. Based upon the annual review, the Company recorded no impairment charges in 2016 and recorded $118,318 in impairment charges in 201 5 .  In 2015, the Company reviewed unamortized costs for patents pending. As a result of this review, the Company determined that the patents pending related to the Triggering Recharging and Wireless Transmission of Remote Patient Monitoring Device, as well as the Seed-Beat Selection Method for Signal-Averaged Electrocardiography were no longer patentable and recorded an impairment charge of $103,287 for the full costs of these patents pending. Additionally, after a review of trade names, the Company determined that the Leominster Tool & Die name no longer provided any future economic benefit and recorded an impairment charge of $15,031 for the remaining unamortized balance of the trade names.  Intangible assets consist of the following:      Estimated December 31, 2016 December 31, 2015  Useful Life Accumulated Accumulated  (in years) Gross Amortization Net Gross Amortization Net  Patents and trademarks 10 $ 26,290 $ 9,738 $ 16,552 $ 26,290 $ 7,981 $ 18,309  Patents and trademarks pending — 13,541 — 13,541 336 — 336  Total intangible assets $ 39,831 $ 9,738 $ 30,093 $ 26,626 $ 7,981 $ 18,645  Amortization expense related to intangible assets, excluding the above noted 2015 impairment charge s , was $1,757 and $3,235 in 2016 and 2015 , respectively. Estimated future annual amortization expense for currently amortizing intangible assets is expected to approximate $1,757 .
Income taxes	Income taxes  The Company recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between the financial statement and tax bases of assets and liabilities using tax rates in effect for the year in which the differences are expected to reverse.  The Company follows the provisions of FASB ASC 740, “Accounting for Uncertainty in Income Taxes—An Interpretation of FASB No. 109.” FASB ASC 740 provides detailed guidance for the financial statement recognition, measurement and disclosure of uncertain tax positions recognized in the financial statements in accordance with SFAS No. 109. Tax positions must meet a “more-likely-than-not” recognition threshold at the effective date to be recognized upon the adoption of FASB ASC 740 and in subsequent periods. No interest and penalties related to uncertain tax positions were accrued at December 31, 201 6 . The Company ’s primary operations are located in the US. Tax years ended December 31, 201 3 or later remain subject to examination by the IRS and state taxing authori ties.
Share-based compensation	Share-based compensation  Share-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized as an expense over the employee’s requisite service period (generally the vesting period of the share-based grant).
Comprehensive loss	Comprehensive loss  In 201 6 and 201 5 , the Company has other comprehensive loss of $0 and $42,502 , respectively. In 2016 , the change in comprehensive loss was a result of the bankruptcy of RMDDx USA Corp . (see Note 12).
Earnings per share data	Earnings per share data  Basic earnings (loss) per share is computed by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding. The computation of diluted earnings (loss) per share is similar to the computation of basic earnings (loss) per share except that the denominator is increased to include the average number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued. In addition, the numerator is adjusted for any changes in net income (loss) that would result from the assumed conversions of those potential shares.
Research and development	Research and development  Research and development expenses include costs directly attributable to conducting research and development programs primarily related to the development of a unique process to improve silver coating during the manufacturing processes, including the design and testing of specific process improvements for certain medical device components. Such costs include salaries, payroll taxes, employee benefit c osts, materials, supplies, depreciation on research equipment, and services provided by outside contractors. All costs associated with research and development programs are expensed as incurred.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements  In the normal course of business, management evaluates all new accounting pronouncements issued by the Financial Accounting Standard Board (“FASB”), Securities and Exchange Commission (“SEC”), Emerging Issues Task Force (“EITF”), or other authoritative accounting bodies to determine the potential impact they may have on the Company’s Consolidated Financial Statements. Based upon this review, except as noted below, management does not expect any of the recently issued accounting pronouncements, which have not already been adopted, to have a material impact on the Company’s consolidated financial statements.  In August 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-15, “ Statement of Cash Flows (Topic 230) Classification of Certain Cash Receipts and Cash Payments” . This standard provides guidance for eight cash flow classification issues in current GAAP. The standard is effective for interim and annual reporting periods beginning after December 15, 2017. The Company is currently evaluating the impact that the standard will have on its consolidated financial statements.  In March 2016, the FASB issued ASU No. 2016-09, “Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting”. The standard is intended to simplify several areas of accounting for share-based compensation arrangements, including the income tax impact, classification on the statement of cash flows and forfeitures. The standard is intended to reduce the cost and complexity with maintaining or improving the usefulness of information provided to users of financial statements. The standard is effective for interim and annual reporting periods beginning after December 15, 2016 and early adoption is permitted. The Company is currently evaluating the impact that the standard will have on its consolidated financial statements.  In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842),” which requires companies to recognize all leases as assets and liabilities on the consolidated balance sheet. The standard retains a distinction between finance leases and operating leases, and the classification criteria for distinguishing between finance leases and operating leases are substantially similar to the classification criteria for distinguishing between capital leases and operating leases in the current accounting literature. The result of retaining a distinction between finance leases and operating leases is that under the lessee accounting model in Topic 842, the effect of leases in a consolidated statement of comprehensive income and a consolidated statement of cash flows is largely unchanged from previous GAAP. The amendments in this standard are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Earlier application is permitted. The Company is currently evaluating the impact that the adoption of this standard will have on its consolidated financial statements.  In November 2015, the FASB issued ASU No. 2015-17, "Balance Sheet Classification of Deferred Taxes" which requires the presentation of deferred tax assets and deferred tax liabilities, and any related valuation allowances, as noncurrent on the consolidated balance sheets. The standard is effective for interim and annual reporting periods beginning after December 15, 2016 and early adoption is permitted. The Company is currently evaluating the impact that the standard will have on its consolidated financial statements.  In July 2015, the FASB issued ASU No. 2015-11, “Simplifying the Measurement of Inventory,” which simplifies the subsequent measurement of inventory by requiring inventory to be measured at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. This standard is effective for public business entities for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. The Company is currently assessing the impact of adopting this standard on its consolidated financial statements.  In April 2015, the FASB issued ASU No. 2015-03, "Simplifying the Presentation of Debt Issuance Costs". ASU 2015-03 requires that debt issuance costs be presented as a direct deduction from the carrying amount of the related debt liability, consistent with the presentation of debt discounts. Prior to the issuance of ASU 2015-03, debt issuance costs were required to be presented as deferred charge assets, separate from the related debt liability. ASU 2015-03 does not change the recognition and measurement requirements for debt issuance costs. The Company adopted ASU 2015-03 as of December 31, 2016, and applied its provisions retrospectively. The adoption of ASU 2015-03 did not have an impact on the Company’s financial results nor did it represent a material change to the consolidated balances sheets.  In August 2014, the FASB issued ASU No. 2014-15, “Presentation of Financial Statements - Going Concern (Subtopic 205-40), Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern”, which requires management to assess a company’s ability to continue as a going concern and to provide related footnote disclosures in certain circumstances. The standard provides guidance on evaluating whether there are conditions or events that raise substantial doubt about an entity’s ability to continue as a going concern. Substantial doubt exists when conditions or events, considered in the aggregate, indicate that it is probable that the entity will be unable to meet its obligations as they become due within one year after the date that the financial statements are issued. The new standard is effective for the annual and interim periods ending after December 15, 2016. The Company adopted the standard in 2016 and management’s assessment has determined that certain disclosures required are included in these statements (see Note 1).  In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers” (“ASU 2014-09”). The core principle behind ASU No. 2014-09 is that an entity should recognize revenue in an amount that reflects the consideration to which the entity expects to be entitled in exchange for delivering goods and services. This model involves a five-step process that includes identifying the contract with the customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations in the contract and recognizing revenue when the entity satisfies the performance obligations. This ASU allows two methods of adoption; a full retrospective approach where historical financial information is presented in accordance with the new standard, and a modified retrospective approach where this ASU is applied to the most current period presented in the financial statements. In August 2015, the FASB issued ASU No 2015-14 “Revenue from Contracts with Customers: Deferral of the Effective Date,” which deferred the effective date of ASU 2014-09 to annual reporting periods beginning after December 15, 2017, with earlier application permitted as of annual reporting periods beginning after December 15, 2016. The Company is currently assessing the financial impact of adopting ASU 2014-09 and the methods of adoption; however, given the scope of the new standard, the Company is currently unable to provide a reasonable estimate regarding the financial impact or which method of adoption will be elected. 
Reclassification of prior period balances	Reclassification of prior period balances  Amounts in prior year financial statements are reclassified when necessary to conform to the current year presentation , most notably debt issuance costs in according with ASU 2015-03 as described more fully above .

Accounting Policies (Tables)

Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Intangibles Assets	   Estimated December 31, 2016 December 31, 2015  Useful Life Accumulated Accumulated  (in years) Gross Amortization Net Gross Amortization Net  Patents and trademarks 10 $ 26,290 $ 9,738 $ 16,552 $ 26,290 $ 7,981 $ 18,309  Patents and trademarks pending — 13,541 — 13,541 336 — 336  Total intangible assets $ 39,831 $ 9,738 $ 30,093 $ 26,626 $ 7,981 $ 18,645 

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2016
Inventories [Abstract]
Inventories	   December 31, December 31,  2016 2015  Raw materials $ 1,027,474 $ 775,427  Work-in-process 537,858 265,113  Finished goods 1,494,753 1,078,172  Total $ 3,060,085 $ 2,118,712 

Property, Plant and Equipment24

Property, Plant and Equipment, net (Tables)	12 Months Ended
	Dec. 31, 2016
Property, Plant and Equipment, net [Abstract]
Property, Plant and Equipment, net	   Asset Lives December 31, December 31,  (in years) 2016 2015  Machinery and equipment 3 to 15 $ 16,647,302 $ 15,168,377  Building and improvements 5 to 25 3,986,715 3,978,387  Vehicles 3 to 5 90,713 90,713  Furniture, fixtures, computers and software 3 to 5 1,504,776 1,437,692  Construction in progress 402,099 682,069  Total property, plant and equipment 22,631,605 21,357,238  Less: accumulated depreciation (16,190,694) (14,731,169)  Property, plant and equipment, net $ 6,440,911 $ 6,626,069 

Debt (Tables)

Debt (Tables)	12 Months Ended
	Dec. 31, 2016
Debt [Abstract]
Summary of Debt	   December 31, December 31,  2016 2015  Revolving line of credit $ 1,785,795 $ 1,511,495  Equipment line of credit $ 102,500 $ 336,850  Subordinated promissory notes, net of discount $ 432,011 $ 473,135   Term notes payable:  Commercial term loan, net of debt issuance costs $ 2,398,870 $ 668,246  Equipment term loans — 879,898  Equipment notes 59,461 116,214  Total term notes payable $ 2,458,331 $ 1,664,358   Total Debt $ 4,778,637 $ 3,985,838 
Future Maturities of Debt	   2017 2018 2019 2020 2021 Thereafter Total  Revolver $ 1,785,795 $ — $ — $ — $ — — $ 1,785,795  Subordinated promissory notes — 450,000 — — — — 450,000  Term debt and equipment notes 513,602 493,337 516,975 541,616 520,782 20,376 2,606,688  Total $ 2,299,397 $ 943,337 $ 516,975 $ 541,616 $ 520,782 20,376 $ 4,842,483 

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2016
Income Taxes [Abstract]
Income Tax Provision	   Years Ended  December 31,  2016 2015  Current:  Federal $ — $ —  State — 932  Total current income taxes — 932  Deferred:  Federal — —  State — —  Total deferred income taxes — —  Total income tax provision $ — $ 932 
Deferred Income Taxes	   Years Ended  December 31,  2016 2015  Deferred tax assets:   Net operating loss carryforwards $ 3,671,600 $ 3,221,000  Federal and state tax credit carryforwards 493,800 608,000  Accruals and reserves 104,600 117,300  Stock based compensation 96,000 89,800  Patents and intangibles 51,100 68,100  Other long-term 500 45,500  Total long-term deferred tax assets 4,417,600 4,149,700   Deferred tax valuation allowance (3,812,900) (3,472,300)  Deferred tax assets, net of allowance 604,700 677,400   Property, plant and equipment (544,000) (612,800)  Prepaid expenses (60,700) (64,600)  Total deferred tax liabilities (604,700) (677,400)   Net deferred tax assets (liabilities) $ — $ — 
Federal Income Taxes	   Years Ended  December 31,  2016 2015  Tax benefit computed at statutory rate $ (250,071) $ (145,442)  Increases (reductions) due to:  Change in valuation allowance 340,600 230,300  State income taxes, net of federal benefit (27,646) 615  Permanent differences 15,124 479  Tax credits (federal and state) (32,577) (108,194)  Differences on prior returns (federal and state) (45,430) 23,174  Income tax (benefit) provision $ — $ 932 

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2016
Shareholders' Equity [Abstract]
Fair Value of Option Grants	   Years Ended  December 31,  2016 2015  Expected option term 6.0 to 6.5 4.0 to 6.5  Expected volatility factor 23.7% to 24.4% 23.8% to 26.7%  Risk-free rate .90% to .99% .90% to 1.28%  Expected annual dividend yield —% —% 
Stock Option Transactions	   Weighted  Weighted average  Average remaining Aggregate  Number of Exercise contractual Intrinsic  options Price term (in years) Value  Outstanding at December 31, 2015 184,500 $ 6.21 6.80 $ 235,293  Granted 45,000 4.07  Exercised (15,000) 3.41  Outstanding at December 31, 2016 214,500 $ 5.96 7.12 $ 17,340  Exercisable at December 31, 2016 109,495 $ 6.90 5.47 $ 8,880  Exercisable at December 31, 2015 83,500 $ 6.60 4.73 $ 106,565 

Earnings Per Share (Tables)

Earnings Per Share (Tables)	12 Months Ended
	Dec. 31, 2016
Earnings Per Share [Abstract]
Calculation of basic and diluted EPS	   Years Ended  December 31,  2016 2015  Loss from continuing operations $ (712,462) $ (791,776)  Income from discontinued operations, net of tax — 362,610  Net loss available to common shareholders $ (712,462) $ (429,166)  Basic EPS:  Weighted average common shares outstanding 2,816,516 2,784,757  Earnings (loss) per share - basic  Continuing operations $ (0.25) $ (0.28)  Discontinued operations — 0.13  Consolidated basic EPS $ (0.25) $ (0.15)  Diluted EPS:  Weighted average common shares outstanding 2,816,516 2,784,757  Assumed conversion of net common shares issuable under stock option plans — —  Assumed conversion of net common shares issuable under warrants — —  Weighted average common and common equivalent shares outstanding, diluted 2,816,516 2,784,757  Earnings (loss) per share - diluted  Continuing operations $ (0.25) $ (0.28)  Discontinued operations — 0.13  Consolidated diluted EPS $ (0.25) $ (0.15) 

Industry and Geographic Segme29

Industry and Geographic Segments (Tables)	12 Months Ended
	Dec. 31, 2016
Industry and Geographic Segments [Abstract]
Sales by Industry Segments	   Revenue for the Years Ended December 31,  2016 % 2015 %  Medical $ 14,543,315 74 $ 16,770,788 78  Automotive/Industrial 3,787,312 19 2,839,926 13  Consumer Products 744,738 4 647,190 4  Military and Law Enforcement 383,254 2 943,603 4  Other 179,598 1 293,677 1  Total $ 19,638,217 100 $ 21,495,184 100 
Sales by Geographic Market	   Revenue for the Years Ended December 31,  2016 % 2015 %  United States $ 12,206,761 62 $ 13,199,188 61  Asia 4,283,180 22 4,774,910 22  Europe 1,677,100 9 1,662,318 9  Canada 1,268,817 6 1,607,445 7  Other 202,359 1 251,323 1  Total $ 19,638,217 100 $ 21,495,184 100 

Description of Business (Detail

Description of Business (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Description of Business [Abstract]
Percent of revenue derived from exports	40.00%
Outstanding balance, line of credit	$ 1,785,795	$ 1,511,495

Accounting Policies (Narrative)

Accounting Policies (Narrative) (Details)	12 Months Ended
	Dec. 31, 2016USD ($)customer	Dec. 31, 2015USD ($)customer
Concentration Risk [Line Items]
General revenue recognition period	3 years
Impairment of intangibles	$ 0	$ 118,318
Amortization expense	1,757	3,235
Estimated future amortization	1,757
Interest or penalties related to unrecognized tax positions	0
Accumulated other comprehensive income	$ 0	$ 42,502
Sales Revenue, Net [Member]
Concentration Risk [Line Items]
Number of customers, concentration of credit risk | customer	2	2
Sales Revenue, Net [Member] | Customer 1 [Member]
Concentration Risk [Line Items]
Concentration of credit risk, percentage	19.00%	16.00%
Sales Revenue, Net [Member] | Customer 2 [Member]
Concentration Risk [Line Items]
Concentration of credit risk, percentage	12.00%	13.00%
Accounts Receivable [Member]
Concentration Risk [Line Items]
Number of customers, concentration of credit risk | customer	5	2
Concentration of credit risk, percentage	46.00%	51.00%
Accounts Receivable [Member] | Customer 1 [Member]
Concentration Risk [Line Items]
Concentration of credit risk, percentage	26.00%	9.00%
Accounts Receivable [Member] | Two Customers [Member]
Concentration Risk [Line Items]
Number of customers, concentration of credit risk | customer	2
Accounts Receivable [Member] | Customer 2 [Member]
Concentration Risk [Line Items]
Concentration of credit risk, percentage	7.00%	9.00%
Patents [Member]
Concentration Risk [Line Items]
Impairment of intangibles	$ 103,287
Trade Names [Member]
Concentration Risk [Line Items]
Impairment of intangibles	$ 15,031

Accounting Policies (Intangible

Accounting Policies (Intangible Assets) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Finite-Lived Intangible Assets [Line Items]
Gross	$ 39,831	$ 26,626
Accumulated Amortization	9,738	7,981
Net	$ 30,093	18,645
Patents and Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (in years)	10 years
Gross	$ 26,290	26,290
Accumulated Amortization	9,738	7,981
Net	16,552	18,309
Patents and Trademarks Pending [Member]
Finite-Lived Intangible Assets [Line Items]
Gross	13,541	336
Net	$ 13,541	$ 336

Inventories (Details)

Inventories (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Inventories [Abstract]
Raw materials	$ 1,027,474	$ 775,427
Work-in-process	537,858	265,113
Finished goods	1,494,753	1,078,172
Total	3,060,085	2,118,712
Silver inventory	$ 521,746	$ 313,738

Property, Plant and Equipment34

Property, Plant and Equipment, net (Narrative) (Details)	Jan. 12, 2017USD ($)	Jan. 31, 2017USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)ft²item	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)ft²
Property, Plant and Equipment [Line Items]
Depreciation expense					$ 1,539,249	$ 1,461,353
Assets held for sale, net			$ 688,750	$ 665,000	688,750	$ 665,000
Escrow Deposit			25,000		$ 25,000
Increase in purchsae price			25,000
Extension fee monthly payment amount			4,000
Extension fee monthly payment amount, additional extension			$ 7,500
Additional extension period for purchase (in days)					150 days
Subsequent Event [Member]
Property, Plant and Equipment [Line Items]
Extension fee monthly payment amount	$ 4,000	$ 4,000
Extension fee monthly payment amount, additional extension	$ 7,500	$ 7,500
Unoccupied Building [Member]
Property, Plant and Equipment [Line Items]
Other income (expense), net					$ 25,000
Fitchburg, Massachusetts [Member]
Property, Plant and Equipment [Line Items]
Number of unoccupied buildings with letter of intent to sale | item				2
Area of building | ft²				52,000		52,000

Property, Plant and Equipment35

Property, Plant and Equipment, net (Property, Plant and Equipment, net) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment
Total property, plant and equipment	$ 22,631,605	$ 21,357,238
Less: accumulated depreciation	(16,190,694)	(14,731,169)
Property, plant and equipment, net	6,440,911	6,626,069
Machinery and Equipment [Member]
Property, Plant and Equipment
Total property, plant and equipment	16,647,302	15,168,377
Building and Improvements [Member]
Property, Plant and Equipment
Total property, plant and equipment	3,986,715	3,978,387
Vehicles [Member]
Property, Plant and Equipment
Total property, plant and equipment	90,713	90,713
Furniture, Fixtures, Computers and Software [Member]
Property, Plant and Equipment
Total property, plant and equipment	1,504,776	1,437,692
Construction in Progress [Member]
Property, Plant and Equipment
Total property, plant and equipment	$ 402,099	$ 682,069
Maximum [Member] | Machinery and Equipment [Member]
Property, Plant and Equipment
Asset Lives (in years)	15 years
Maximum [Member] | Building and Improvements [Member]
Property, Plant and Equipment
Asset Lives (in years)	25 years
Maximum [Member] | Vehicles [Member]
Property, Plant and Equipment
Asset Lives (in years)	5 years
Maximum [Member] | Furniture, Fixtures, Computers and Software [Member]
Property, Plant and Equipment
Asset Lives (in years)	5 years
Minimum [Member] | Machinery and Equipment [Member]
Property, Plant and Equipment
Asset Lives (in years)	3 years
Minimum [Member] | Building and Improvements [Member]
Property, Plant and Equipment
Asset Lives (in years)	5 years
Minimum [Member] | Vehicles [Member]
Property, Plant and Equipment
Asset Lives (in years)	3 years
Minimum [Member] | Furniture, Fixtures, Computers and Software [Member]
Property, Plant and Equipment
Asset Lives (in years)	3 years

Debt (Bank Debt Narrative) (Det

Debt (Bank Debt Narrative) (Details)	1 Months Ended	12 Months Ended
	Nov. 30, 2016USD ($)item	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)item	Jun. 30, 2016USD ($)
Debt Instrument [Line Items]
Number of Equipment Term Loans | item	4		2
Proceeds from term note payable		$ 500,000	$ 0
Outstanding balance, line of credit		1,785,795	1,511,495
Debt issuance costs		$ 45,858	45,929
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Percent Borrowable of net Elegible Recievable		80.00%
Percent Borrowable of net Eligible Raw Materials Inventory		50.00%
Revolver, interest rate at end of period		4.00%
Amount available under line of credit facility		$ 727,156
Maximum borrowing capacity	$ 500,000,000
Revolving Credit Facility [Member] | Prime Rate [Member]
Debt Instrument [Line Items]
Spread on variable rate		0.25%
Commercial Term Loan [Member]
Debt Instrument [Line Items]
Number of debt instruments converted during period | item	1
Debt instrument, interest rate	4.65%
Debt maturity period		5 years
Approximate monthly principal and interest payment	$ 46,500
Debt instrument, face amount	$ 2,481,943
Equipment Term Loan [Member]
Debt Instrument [Line Items]
Number of debt instruments converted during period | item	3
Equipment Line Of Credit 2013 [Member] | Equipment Line of Credit [Member]
Debt Instrument [Line Items]
Line of credit, draw period		1 year
Line of Credit Facility, Expiration Period		5 years
Maximum borrowing capacity		$ 1,000,000
Outstanding balance, line of credit	$ 380,791	$ 740,999
Equipment Line Of Credit 2014 [Member] | Equipment Line of Credit [Member]
Debt Instrument [Line Items]
Line of credit, draw period		1 year
Line of Credit Facility, Expiration Period		5 years
Maximum borrowing capacity		$ 1,000,000
Outstanding balance, line of credit	315,272	$ 415,785
Equipment Term Loan 2015 [Member]
Debt Instrument [Line Items]
Debt outstanding, principal and accrued interest	832,420
Equipment Term Loan 2015 [Member] | Equipment Line of Credit [Member]
Debt Instrument [Line Items]
Outstanding balance, line of credit				$ 881,701
Equipment Line Of Credit 2015 [Member] | Equipment Line of Credit [Member]
Debt Instrument [Line Items]
Line of credit, draw period		1 year
Maximum borrowing capacity			1,000,000
Outstanding balance, line of credit			$ 336,850
Equipment Term Loan 2016 [Member] | Equipment Line of Credit [Member]
Debt Instrument [Line Items]
Line of credit, draw period		1 year
Outstanding balance, line of credit	$ 1,000,000	$ 102,500
Line of credit, maturity period		6 years
Earliest repayment period, from date of loan		1 year
Equipment Term Loan 2016 [Member] | Equipment Line of Credit [Member] | Prime Rate [Member]
Debt Instrument [Line Items]
Spread on variable rate		0.25%

Debt (Other Debt Narrative) (De

Debt (Other Debt Narrative) (Details)	1 Months Ended			12 Months Ended
	Nov. 30, 2016item	Oct. 31, 2016item	Jan. 31, 2013USD ($)item	Dec. 31, 2016USD ($)item$ / sharesshares	Dec. 31, 2015USD ($)itemshares	Dec. 31, 2014shares	Dec. 31, 2013USD ($)shares
Debt Instruments [Line Items]
Number Of Debt Instruments | item	4				2
Payment on subordinated debt				$ 50,000	$ 0
Number of warrants issued | shares				100,000
Issuance of common stock from treasury, shares | shares				15,000	23,300	30,000
Warrants unexercised | shares				70,000	70,000		100,000
Subordinated promissory notes, exercise price of warrants | $ / shares				$ 3.51
REF Securities, LLP [Member]
Debt Instruments [Line Items]
Number of warrants issued | shares				20,000
Chambers Medical Foundation [Member]
Debt Instruments [Line Items]
Number of warrants issued | shares				20,000
Issuance of common stock from treasury, shares | shares						20,000
E.P. Marinos [Member]
Debt Instruments [Line Items]
Number of warrants issued | shares				10,000
Warrants [Member]
Debt Instruments [Line Items]
Issuance of common stock from treasury, shares | shares				0	0	30,000
Term Debt And Equipment Notes [Member] | Equipment Term Loans [Member]
Debt Instruments [Line Items]
Number Of Debt Instruments | item			2
Debt instrument, face amount			$ 272,500
Debt instrument, interest rate				4.66%
Approximate monthly principal and interest payment				$ 5,000
Equipment notes, maturity period				5 years
Subordinated Promissory Notes [Member]
Debt Instruments [Line Items]
Debt instrument, face amount				$ 450,000			$ 500,000
Debt instrument, maturity date				Dec. 31, 2018
Interest rate				10.00%	12.00%	10.00%	10.00%
Payment on subordinated debt				$ 50,000
Number of investors in the private offering | item		7
Number of investors, maturity date extended | item		6
Number of investors, maturity date not extended | item				1
Debt, fair value				$ 18,310
Number of largest beneficial owners | item				2
Subordinated Promissory Notes [Member] | REF Securities, LLP [Member]
Debt Instruments [Line Items]
Percent of beneficial owner of company's common stock				13.00%
Invested amount in private offering				$ 100,000
Subordinated Promissory Notes [Member] | Chambers Medical Foundation [Member]
Debt Instruments [Line Items]
Percent of beneficial owner of company's common stock				10.00%
Invested amount in private offering				$ 100,000
Subordinated Promissory Notes [Member] | E.P. Marinos [Member]
Debt Instruments [Line Items]
Invested amount in private offering				50,000
Subordinated Promissory Notes [Member] | Three Related Parties [Member]
Debt Instruments [Line Items]
Debt instrument, face amount				$ 250,000

Debt (Summary of Debt) (Details

Debt (Summary of Debt) (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Revolving line of credit	$ 1,785,795	$ 1,511,495
Equipment line of credit	102,500	336,850
Subordinated promissory notes, net of discount	432,011	473,135
Total Debt	4,778,637	3,985,838
Term Debt And Equipment Notes [Member]
Debt Instrument [Line Items]
Total term notes payable	2,458,331	1,664,358
Term Debt And Equipment Notes [Member] | Commercial Term Loan [Member]
Debt Instrument [Line Items]
Total term notes payable	2,398,870	668,246
Term Debt And Equipment Notes [Member] | Equipment Term Loans [Member]
Debt Instrument [Line Items]
Total term notes payable		879,898
Term Debt And Equipment Notes [Member] | Equipment Notes [Member]
Debt Instrument [Line Items]
Total term notes payable	$ 59,461	$ 116,214

Debt (Future Minimum of Debt) (

Debt (Future Minimum of Debt) (Details)	Dec. 31, 2016USD ($)
Future maturities of debt
2,017	$ 2,299,397
2,018	943,337
2,019	516,975
2,020	541,616
2,021	520,782
Thereafter	20,376
Long-term Debt, Total	4,842,483
Revolving Credit Facility [Member]
Future maturities of debt
2,017	1,785,795
2,018	0
2,019	0
2,020	0
2,021	0
Thereafter	0
Long-term Debt, Total	1,785,795
Subordinated Promissory Notes [Member]
Future maturities of debt
2,017	0
2,018	450,000
2,019	0
2,020	0
2,021	0
Thereafter	0
Long-term Debt, Total	450,000
Term Debt And Equipment Notes [Member]
Future maturities of debt
2,017	513,602
2,018	493,337
2,019	516,975
2,020	541,616
2,021	520,782
Thereafter	20,376
Long-term Debt, Total	$ 2,606,688

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Income Taxes [Line Items]
Income tax provision		$ 932
Federal statutory income tax rate	34.00%
Federal Tax Authority [Member]
Income Taxes [Line Items]
Net operating loss carryforwards	$ 9,124,000
Tax credit carryforwards	305,800
State Jurisdiction [Member]
Income Taxes [Line Items]
Net operating loss carryforwards	10,780,000
Tax credit carryforwards	$ 188,000

Income Taxes (Income Tax Provis

Income Taxes (Income Tax Provision) (Details)	12 Months Ended
	Dec. 31, 2015USD ($)
Current:
State	$ 932
Total current income taxes	932
Income tax provision	$ 932

Income Taxes (Deferred Income T

Income Taxes (Deferred Income Taxes) (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Deferred income taxes:
Net operating loss carryforwards	$ 3,671,600	$ 3,221,000
Federal and state tax credit carryforward	493,800	608,000
Accruals and reserves	104,600	117,300
Stock compensation	96,000	89,800
Patents and intangibles	51,100	68,100
Other long-term	500	45,500
Total long-term deferred tax assets	4,417,600	4,149,700
Deferred tax valuation allowance	(3,812,900)	(3,472,300)
Deferred tax assets, net of allowance	604,700	677,400
Prepaid expenses	(60,700)	(64,600)
Property, plant and equipment	(544,000)	(612,800)
Total deferred tax liabilities	(604,700)	(677,400)
Net deferred tax assets (liabilities)	$ 0	$ 0

Income Taxes (Federal Income Ta

Income Taxes (Federal Income Taxes) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Income Taxes [Abstract]
Tax benefit computed at statutory rate	$ (250,071)	$ (145,442)
Change in valuation allowance	340,600	230,300
State income taxes, net of federal benefit	(27,646)	615
Permanent differences	15,124	479
Tax credits (federal and state)	(32,577)	(108,194)
Differences on prior returns (federal and state)	$ (45,430)	23,174
Income tax provision		$ 932

Employee Benefit Plans (Details

Employee Benefit Plans (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Employee Benefit Plans [Abstract]
Maximum annual contribution per employee, percent of eligible compensation	90.00%
Matching 401K contribution	$ 41,072	$ 47,858

Commitments and Contingencies (

Commitments and Contingencies (Details)	12 Months Ended
	Dec. 31, 2016USD ($)agreement
Commitments and Contingencies [Abstract]
Number of operating lease agreements | agreement	2
Operating lease payments due in 2017	$ 24,036
Operating lease payments due in 2018	$ 24,036

Shareholders' Equity (Narrative

Shareholders' Equity (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance of common stock from treasury, shares	15,000	23,300	30,000
Dividends declared or paid	$ 0	$ 0
Subordinated promissory notes, exercise price of warrants	$ 3.51
Warrants unexercised	70,000	70,000		100,000
Options outstanding	214,500	184,500
Shares available for future grants	273,000
Number of options, granted in period	45,000	62,500
Intrinsic value of options exercised	$ 30,600	$ 60,197
Number of options, exercised in period	15,000
Share-based compensation expense	$ 47,256	29,178
Unrecognized compensation costs related to non-vested shares	$ 134,354	$ 134,160
Unrecognized compensation costs, recognized over weighted average period	2 years 8 months 12 days
Weighted average grant date fair value	$ 1.05
The 2010 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized for issuance	500,000
The 2010 Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Contractual Term	10 years
Vesting period	5 years
The 2010 Plan [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Treasury stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance of common stock from treasury, shares	15,000	23,300
Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance of common stock from treasury, shares	0	0	30,000

Shareholders' Equity (Fair Valu

Shareholders' Equity (Fair Value of Option Grants) (Details)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Minimum [Member]
Fair Value, Option, Quantitative Disclosures [Line Items]
Expected option term, years	6 years	4 years
Expected volatility factor	23.70%	23.80%
Risk-free rate	0.90%	0.90%
Maximum [Member]
Fair Value, Option, Quantitative Disclosures [Line Items]
Expected option term, years	6 years 6 months	6 years 6 months
Expected volatility factor	24.40%	26.70%
Risk-free rate	0.99%	1.28%

Shareholders' Equity (Stock Opt

Shareholders' Equity (Stock Option Transactions) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Shareholders' Equity [Abstract]
Number of options, outstanding, beginning balance	184,500
Weighted average exercise price, options outstanding	$ 5.96	$ 6.21
Weighted average remaining contractual term (in years), options outstanding	7 years 1 month 13 days	6 years 9 months 18 days
Aggregate intrinsic value, options outstanding	$ 17,340	$ 235,293
Number of options, granted in period	45,000	62,500
Weighted average exercise price, options granted in period	$ 4.07
Number of options, exercised in period	(15,000)
Weighted average exercise price, options exercised in period	$ 3.41
Number of options, outstanding, ending balance	214,500	184,500
Number of options, exercisable	109,495	83,500
Weighted average exercise price, options exercisable	$ 6.90	$ 6.60
Weighted average remaining contractual term (in years), options exercisable	5 years 5 months 19 days	4 years 8 months 23 days
Aggregate intrinsic value, options exercisable	$ 8,880	$ 106,565

Earnings Per share (Narrative)

Earnings Per share (Narrative) (Details) - shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Warrants to purchase outstanding	70,000	70,000	100,000
Employee Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares	214,500	184,500

Earnings Per share (Calculation

Earnings Per share (Calculation of basic and diluted EPS) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Earnings Per Share [Abstract]
Loss from continuing operations	$ (712,462)	$ (791,776)
Income from discontinued operations, net of tax	0	362,610
Net loss	$ (712,462)	$ (429,166)
Basic EPS:
Weighted average common shares outstanding	2,816,516	2,784,757
Earnings (loss) per share - basic
Continuing operations	$ (0.25)	$ (0.28)
Discontinued operations	0	0.13
Earnings (loss) per share - basic	$ (0.25)	$ (0.15)
Diluted EPS:
Weighted average common shares outstanding	2,816,516	2,784,757
Assumed conversion of net common shares issuable under stock option plans	0	0
Assumed conversion of net common shares issuable under warrants	0	0
Weighted average common and common equivalent shares outstanding, diluted	2,816,516	2,784,757
Earnings (loss) per share - diluted
Continuing operations	$ (0.25)	$ (0.28)
Discontinued operations	0	0.13
Earnings (loss) per share - dilutes	$ (0.25)	$ (0.15)

Industry and Geographic Segme51

Industry and Geographic Segments (Sales by Industry Segments) (Details)	12 Months Ended
	Dec. 31, 2016USD ($)segment	Dec. 31, 2015USD ($)
Segment Reporting Information [Line Items]
Revenues	$ 19,638,217	$ 21,495,184
Revenue by Percent	100.00%	100.00%
Number of operating segments | segment	1
Medical [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenues	$ 14,543,315	$ 16,770,788
Revenue by Percent	74.00%	78.00%
Automotive/Industrial [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenues	$ 3,787,312	$ 2,839,926
Revenue by Percent	19.00%	13.00%
Consumer Products [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenues	$ 744,738	$ 647,190
Revenue by Percent	4.00%	4.00%
Military and Law Enforcement [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenues	$ 383,254	$ 943,603
Revenue by Percent	2.00%	4.00%
Other Product/Service [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenues	$ 179,598	$ 293,677
Revenue by Percent	1.00%	1.00%

Industry and Geographic Segme52

Industry and Geographic Segments (Sales by Geographic Market) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	$ 19,638,217	$ 21,495,184
Revenue by Percent	100.00%	100.00%
United States [Member] | Operating Segments [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	$ 12,206,761	$ 13,199,188
Revenue by Percent	62.00%	61.00%
Asia [Member] | Operating Segments [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	$ 4,283,180	$ 4,774,910
Revenue by Percent	22.00%	22.00%
Europe [Member] | Operating Segments [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	$ 1,677,100	$ 1,662,318
Revenue by Percent	9.00%	9.00%
Canada [Member] | Operating Segments [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	$ 1,268,817	$ 1,607,445
Revenue by Percent	6.00%	7.00%
Other Geographic Markets [Member] | Operating Segments [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	$ 202,359	$ 251,323
Revenue by Percent	1.00%	1.00%

Discontinued Operations (Detail

Discontinued Operations (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Discontinued Operations [Abstract]
Income from discontinued operations, net of tax	$ 0	$ 362,610

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)	Jan. 12, 2017	Jan. 31, 2017	Dec. 31, 2016
Subsequent Event [Line Items]
Extension fee monthly payment amount			$ 4,000
Extension Fee Monthly Payment Amount, Additional Extension			$ 7,500
Subsequent Event [Member]
Subsequent Event [Line Items]
Extension fee monthly payment amount	$ 4,000	$ 4,000
Extension Fee Monthly Payment Amount, Additional Extension	$ 7,500	$ 7,500